Xeris Biopharma Holdings, Inc.
Price Action
Technical Summary
CONSOLIDATINGXeris Biopharma Holdings, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 67), indicating performance broadly in line with the market. Earnings growth of 121% provides fundamental context to the price action. However, price is extended 20% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $6.69 | +14.91% | ABOVE |
| 50 SMA | $6.40 | +20.08% | ABOVE |
| 100 SMA | $6.28 | +22.54% | ABOVE |
| 150 SMA | $6.60 | +16.56% | ABOVE |
| 200 SMA | $7.03 | +9.40% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is XERS in an uptrend right now?
XERS has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is XERS overbought or oversold?
XERS's RSI (14) is 73. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is XERS outperforming the market?
XERS has a Relative Strength (RS) Rating of 67 out of 99. XERS is performing about average compared to the market.
Where is XERS in its 52-week range?
XERS is trading at $7.69, which is 76% of its 52-week high ($10.08) and 57% above its 52-week low ($4.52).
How volatile is XERS?
XERS has a Beta of 0.81 and 52-week volatility of 56%. It's less volatile than the S&P 500 - generally more stable.